MICHAEL BIGHAM - 08 Aug 2022 Form 4 Insider Report for Paratek Pharmaceuticals, Inc.

Role
Exec. Chairman of the Board, Director
Signature
/s/ William M. Haskell, Attorney-in-Fact for Michael Bigham
Issuer symbol
N/A
Transactions as of
08 Aug 2022
Net transactions value
-$76,174
Form type
4
Filing time
10 Aug 2022, 21:00:33 UTC
Previous filing
23 Mar 2022
Next filing
27 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRTK Common Stock Award $0 +143,182 +13% $0.000000 1,236,464 08 Aug 2022 Direct F1
transaction PRTK Common Stock Sale $76,174 -28,637 -2.3% $2.66 1,207,827 09 Aug 2022 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

MICHAEL BIGHAM is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents performance-based restricted stock units ("PRSUs") granted on February 19, 2020 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on August 8, 2022.
F2 Sale of shares to cover personal income tax obligations upon vesting of PRSUs, pursuant to Rule 10b5-1 trading plan.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $2.58 to $2.78. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4.